Annual FCF
-$408.07 M
-$16.39 M-4.19%
December 31, 2023
Summary
- As of February 8, 2025, NTLA annual free cash flow is -$408.07 million, with the most recent change of -$16.39 million (-4.19%) on December 31, 2023.
- During the last 3 years, NTLA annual FCF has fallen by -$354.57 million (-662.79%).
- NTLA annual FCF is now -1462.78% below its all-time high of $29.94 million, reached on December 31, 2016.
Performance
NTLA Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
-$86.12 M
-$26.92 M-45.47%
September 30, 2024
Summary
- As of February 8, 2025, NTLA quarterly free cash flow is -$86.12 million, with the most recent change of -$26.92 million (-45.47%) on September 30, 2024.
- Over the past year, NTLA quarterly FCF has increased by +$19.60 million (+18.54%).
- NTLA quarterly FCF is now -229.69% below its all-time high of $66.40 million, reached on June 30, 2016.
Performance
NTLA Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM FCF
-$363.06 M
+$19.60 M+5.12%
September 30, 2024
Summary
- As of February 8, 2025, NTLA TTM free cash flow is -$363.06 million, with the most recent change of +$19.60 million (+5.12%) on September 30, 2024.
- Over the past year, NTLA TTM FCF has increased by +$44.22 million (+10.86%).
- NTLA TTM FCF is now -893.30% below its all-time high of $45.77 million, reached on June 30, 2016.
Performance
NTLA TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
NTLA Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -4.2% | +18.5% | +10.9% |
| 3 y3 years | -662.8% | -23.8% | -63.9% |
| 5 y5 years | -503.5% | -216.7% | -229.9% |
NTLA Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -71.6% | at low | -49.7% | +31.7% | -52.7% | +13.2% |
| 5 y | 5-year | -662.8% | at low | -252.7% | +31.7% | -776.1% | +13.2% |
| alltime | all time | -1462.8% | at low | -229.7% | +31.7% | -893.3% | +13.2% |
Intellia Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$86.12 M(+45.5%) | -$363.06 M(-5.1%) |
| Jun 2024 | - | -$59.20 M(-51.9%) | -$382.65 M(-8.5%) |
| Mar 2024 | - | -$123.17 M(+30.2%) | -$418.08 M(+2.5%) |
| Dec 2023 | -$408.07 M(+4.2%) | -$94.57 M(-10.5%) | -$408.07 M(+0.2%) |
| Sep 2023 | - | -$105.71 M(+11.7%) | -$407.28 M(+6.0%) |
| Jun 2023 | - | -$94.62 M(-16.4%) | -$384.33 M(+1.5%) |
| Mar 2023 | - | -$113.16 M(+20.7%) | -$378.77 M(-3.3%) |
| Dec 2022 | -$391.68 M(+64.7%) | -$93.78 M(+13.3%) | -$391.68 M(+10.2%) |
| Sep 2022 | - | -$82.76 M(-7.1%) | -$355.42 M(+3.9%) |
| Jun 2022 | - | -$89.07 M(-29.3%) | -$342.21 M(+10.7%) |
| Mar 2022 | - | -$126.06 M(+119.2%) | -$309.06 M(+30.0%) |
| Dec 2021 | -$237.79 M(+344.5%) | -$57.52 M(-17.3%) | -$237.79 M(+7.4%) |
| Sep 2021 | - | -$69.56 M(+24.4%) | -$221.50 M(+22.2%) |
| Jun 2021 | - | -$55.92 M(+2.1%) | -$181.19 M(+163.0%) |
| Mar 2021 | - | -$54.79 M(+32.9%) | -$68.89 M(+28.8%) |
| Dec 2020 | -$53.50 M(-51.4%) | -$41.23 M(+40.9%) | -$53.50 M(+23.0%) |
| Sep 2020 | - | -$29.26 M(-151.9%) | -$43.50 M(+5.0%) |
| Jun 2020 | - | $56.38 M(-243.1%) | -$41.44 M(-67.2%) |
| Mar 2020 | - | -$39.39 M(+26.1%) | -$126.44 M(+14.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2019 | -$110.03 M(+62.7%) | -$31.23 M(+14.8%) | -$110.03 M(+23.7%) |
| Sep 2019 | - | -$27.20 M(-5.0%) | -$88.93 M(+16.7%) |
| Jun 2019 | - | -$28.62 M(+24.5%) | -$76.20 M(+7.4%) |
| Mar 2019 | - | -$22.99 M(+126.9%) | -$70.98 M(+5.0%) |
| Dec 2018 | -$67.61 M(-10.3%) | -$10.13 M(-30.0%) | -$67.61 M(-16.7%) |
| Sep 2018 | - | -$14.47 M(-38.1%) | -$81.19 M(-5.5%) |
| Jun 2018 | - | -$23.39 M(+19.2%) | -$85.87 M(+8.1%) |
| Mar 2018 | - | -$19.62 M(-17.2%) | -$79.43 M(+5.4%) |
| Dec 2017 | -$75.37 M(-351.7%) | -$23.70 M(+23.7%) | -$75.37 M(+8.5%) |
| Sep 2017 | - | -$19.15 M(+13.0%) | -$69.48 M(+18.7%) |
| Jun 2017 | - | -$16.95 M(+8.9%) | -$58.54 M(-335.9%) |
| Mar 2017 | - | -$15.56 M(-12.7%) | $24.81 M(-17.1%) |
| Dec 2016 | $29.94 M(-793.6%) | -$17.82 M(+116.9%) | $29.94 M(-27.7%) |
| Sep 2016 | - | -$8.21 M(-112.4%) | $41.42 M(-9.5%) |
| Jun 2016 | - | $66.40 M(-736.7%) | $45.77 M(-340.2%) |
| Mar 2016 | - | -$10.43 M(+64.5%) | -$19.05 M(+341.3%) |
| Dec 2015 | -$4.32 M | -$6.34 M(+63.9%) | -$4.32 M(-313.4%) |
| Sep 2015 | - | -$3.87 M(-343.9%) | $2.02 M(-65.7%) |
| Jun 2015 | - | $1.59 M(-63.2%) | $5.89 M(+36.8%) |
| Mar 2015 | - | $4.31 M | $4.31 M |
FAQ
- What is Intellia Therapeutics annual free cash flow?
- What is the all time high annual FCF for Intellia Therapeutics?
- What is Intellia Therapeutics annual FCF year-on-year change?
- What is Intellia Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Intellia Therapeutics?
- What is Intellia Therapeutics quarterly FCF year-on-year change?
- What is Intellia Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Intellia Therapeutics?
- What is Intellia Therapeutics TTM FCF year-on-year change?
What is Intellia Therapeutics annual free cash flow?
The current annual FCF of NTLA is -$408.07 M
What is the all time high annual FCF for Intellia Therapeutics?
Intellia Therapeutics all-time high annual free cash flow is $29.94 M
What is Intellia Therapeutics annual FCF year-on-year change?
Over the past year, NTLA annual free cash flow has changed by -$16.39 M (-4.19%)
What is Intellia Therapeutics quarterly free cash flow?
The current quarterly FCF of NTLA is -$86.12 M
What is the all time high quarterly FCF for Intellia Therapeutics?
Intellia Therapeutics all-time high quarterly free cash flow is $66.40 M
What is Intellia Therapeutics quarterly FCF year-on-year change?
Over the past year, NTLA quarterly free cash flow has changed by +$19.60 M (+18.54%)
What is Intellia Therapeutics TTM free cash flow?
The current TTM FCF of NTLA is -$363.06 M
What is the all time high TTM FCF for Intellia Therapeutics?
Intellia Therapeutics all-time high TTM free cash flow is $45.77 M
What is Intellia Therapeutics TTM FCF year-on-year change?
Over the past year, NTLA TTM free cash flow has changed by +$44.22 M (+10.86%)